JP2017516827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516827A5 JP2017516827A5 JP2016571105A JP2016571105A JP2017516827A5 JP 2017516827 A5 JP2017516827 A5 JP 2017516827A5 JP 2016571105 A JP2016571105 A JP 2016571105A JP 2016571105 A JP2016571105 A JP 2016571105A JP 2017516827 A5 JP2017516827 A5 JP 2017516827A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- prochlorperazine
- group
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 229960004768 irinotecan Drugs 0.000 claims 7
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 6
- 229930012538 Paclitaxel Natural products 0.000 claims 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 6
- -1 bevacizumab Chemical compound 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 6
- 229960004316 cisplatin Drugs 0.000 claims 6
- 229960002949 fluorouracil Drugs 0.000 claims 6
- 206010017758 gastric cancer Diseases 0.000 claims 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 6
- 229960005277 gemcitabine Drugs 0.000 claims 6
- 229960001756 oxaliplatin Drugs 0.000 claims 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 6
- 229960001592 paclitaxel Drugs 0.000 claims 6
- 229960005079 pemetrexed Drugs 0.000 claims 6
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 6
- 201000011549 stomach cancer Diseases 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 5
- 229960003111 prochlorperazine Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- ZWIQAXTYRCAVFE-UHFFFAOYSA-N 2-chloro-10-(3-piperazin-1-ylpropyl)phenothiazine Chemical compound C12=CC(Cl)=CC=C2SC2=CC=CC=C2N1CCCN1CCNCC1 ZWIQAXTYRCAVFE-UHFFFAOYSA-N 0.000 claims 4
- AZGYHFQQUZPAFZ-UHFFFAOYSA-N 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine 5-oxide Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2S(=O)C2=CC=CC=C21 AZGYHFQQUZPAFZ-UHFFFAOYSA-N 0.000 claims 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 4
- 229960001433 erlotinib Drugs 0.000 claims 4
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 4
- 201000000496 gastric squamous cell carcinoma Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462006630P | 2014-06-02 | 2014-06-02 | |
| US62/006,630 | 2014-06-02 | ||
| PCT/CN2015/000380 WO2015184794A1 (en) | 2014-06-02 | 2015-06-02 | Method for treating drug resistant cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516827A JP2017516827A (ja) | 2017-06-22 |
| JP2017516827A5 true JP2017516827A5 (enExample) | 2018-07-12 |
Family
ID=54766042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571105A Pending JP2017516827A (ja) | 2014-06-02 | 2015-06-02 | 薬剤耐性がんの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170105999A1 (enExample) |
| EP (1) | EP3148547B1 (enExample) |
| JP (1) | JP2017516827A (enExample) |
| KR (1) | KR102053507B1 (enExample) |
| CN (1) | CN106794184A (enExample) |
| AU (2) | AU2015271561A1 (enExample) |
| CA (1) | CA2963269A1 (enExample) |
| TW (1) | TWI735413B (enExample) |
| WO (1) | WO2015184794A1 (enExample) |
| ZA (1) | ZA201608820B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695138B1 (en) * | 2016-10-17 | 2017-07-04 | Acenda Pharma, Inc. | Phenothiazine derivatives and methods of use thereof |
| WO2019204764A1 (en) * | 2018-04-19 | 2019-10-24 | Washington University | Compositions and methods of use thereof for treatment of proteinopathies |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| CN113264903A (zh) * | 2021-05-27 | 2021-08-17 | 郑州大学 | 一种吩噻嗪类化合物及其制备方法和应用 |
| US20250044294A1 (en) * | 2023-07-31 | 2025-02-06 | National Yang Ming Chiao Tung University | Composition and method of treating a cancer through affecting membrane receptors of cancer cells and their derived extracellular vesicles |
| KR20250094197A (ko) | 2023-12-18 | 2025-06-25 | 서울대학교산학협력단 | 신규 베타-카볼린 유도체 및 이를 포함하는 약물 내성 암 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185243C (zh) | 1999-10-26 | 2005-01-19 | 中国人民解放军第二军医大学 | 一种防治心脑血管疾病的四羟基二苯乙烯苷类新化合物 |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| JP2009515896A (ja) * | 2005-11-11 | 2009-04-16 | ファイザー・インク | 免疫調節性オリゴデオキシヌクレオチドを使用する併用療法 |
| CA2677651A1 (en) * | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CN103687853B (zh) * | 2011-04-29 | 2017-12-08 | 宾夕法尼亚大学托管会 | 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途 |
| JP2014516964A (ja) * | 2011-05-18 | 2014-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用抗ｉｇｆ１ｒ合剤 |
| WO2013070688A1 (en) * | 2011-11-11 | 2013-05-16 | Yale University | Reprogramming urokinase into an antibody-recruiting anticancer agent |
| US8809299B2 (en) * | 2012-03-28 | 2014-08-19 | Mcmaster University | Combination therapy for the treatment of cancer |
-
2015
- 2015-06-02 JP JP2016571105A patent/JP2017516827A/ja active Pending
- 2015-06-02 AU AU2015271561A patent/AU2015271561A1/en not_active Abandoned
- 2015-06-02 CA CA2963269A patent/CA2963269A1/en not_active Abandoned
- 2015-06-02 US US15/316,079 patent/US20170105999A1/en not_active Abandoned
- 2015-06-02 CN CN201580035554.8A patent/CN106794184A/zh active Pending
- 2015-06-02 TW TW104117852A patent/TWI735413B/zh not_active IP Right Cessation
- 2015-06-02 WO PCT/CN2015/000380 patent/WO2015184794A1/en not_active Ceased
- 2015-06-02 KR KR1020177000067A patent/KR102053507B1/ko active Active
- 2015-06-02 EP EP15802818.3A patent/EP3148547B1/en active Active
-
2016
- 2016-12-21 ZA ZA2016/08820A patent/ZA201608820B/en unknown
-
2018
- 2018-08-27 AU AU2018222881A patent/AU2018222881A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516827A5 (enExample) | ||
| JP2019508440A5 (enExample) | ||
| JP2016538344A5 (enExample) | ||
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| JP2018529656A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| ME02395B (me) | Kombinovana terapija sa antitumorskim alkaloidima | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JP2015536964A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| JP2017517520A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| RU2010140890A (ru) | Улучшенные способы противоопухолевого лечения | |
| JP2019521180A5 (enExample) | ||
| MA40075A (fr) | Combinaisons pour traiter des cancers | |
| RU2018134336A (ru) | Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина | |
| JP2019506392A5 (enExample) | ||
| JP2016502981A5 (enExample) | ||
| JP2019510075A5 (enExample) | ||
| HK1247837A1 (zh) | 1-甲基-d-色氨酸的盐和前药 | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака |